Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 33,170 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Frailty
Interventions: Ghrelin Infusion - Healthy, Ghrelin Infusion - Frail, Placebo Infusion -Healthy, Placebo Infusion - Frail; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 70 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers
Interventions: Atumelnant, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteers
Interventions: MA-0211, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Lamotrigine, BI 409306, Placebo, BI 425809; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Obesity, Prediabetic State
Interventions: Melatonin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
Interventions: Romosozumab Prefilled Syringe, Placebo, Zoledronic acid 5 mg; Drug
Lead sponsor: Karen Klahr Miller, MD; Other
Eligibility: 20 Years to 60 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Venous Thromboembolism, Cancer, Cardiovascular Events
Interventions: Rosuvastatin, Placebo Drug; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 9
States / cities: Irvine, California • New Haven, Connecticut • Miami, Florida + 4 more

Conditions: Stuttering, Adult
Interventions: Aripiprazole 10 MG, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Interventions: OPL-0401 Dose 1, Placebo; Drug
Lead sponsor: Valo Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 25
States / cities: Mountain View, California • Riverside, California • Sacramento, California + 20 more

Conditions: Obesity
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypoxia
Interventions: Ketone ester, Placebo; Dietary Supplement · Other
Lead sponsor: Florida Institute for Human and Machine Cognition; Other
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Pensacola, Florida

Conditions: COVID-19
Interventions: APX-115, Placebo; Drug
Lead sponsor: Aptabio Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Little Rock, Arkansas • Annapolis, Maryland • Wyoming, Michigan + 3 more

Conditions: Healthy Male Volunteer
Interventions: JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg), Placebo, Midazolam and JNJ-38518168; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cypress, California

Conditions: Nausea, Vomiting
Interventions: ABH gel, placebo; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Concussion, Brain, Concussion, Mild, Concussion
Interventions: BCAA, Placebo; Drug · Other
Lead sponsor: Akiva Cohen; Other
Eligibility: 11 Years to 23 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Long COVID
Interventions: Lithium, Placebo; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 34
States / cities: Sheffield, Alabama • Lincoln, California • Newport Beach, California + 31 more

Conditions: Healthy, no Evidence of Disease
Interventions: retinoid 9cUAB30, placebo, pharmacological study, laboratory biomarker analysis, cancer prevention; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions: Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab; Drug · Combination Product
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 57
States / cities: Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more

Conditions: Pulmonary Hypertension
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 18
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more

Conditions: Overactive Bladder
Interventions: SSR240600C, Placebo, Tolterodine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 22
States / cities: Phoenix, Arizona • Tuscon, Arizona • San Diego, California + 19 more

Conditions: Diabetic Foot Ulcers, Diabetic Foot Wounds
Interventions: Collagenase Santyl Ointment, Placebo Comparator; Biological · Other
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy Volunteers, Pharmacokinetics of ASP1941
Interventions: ASP1941, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Aspergillosis/Blood, Aspergillosis/Invasive
Interventions: micafungin, voriconazole; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 44
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 41 more

Search by objective public record fields.

Ghrelin in Healthy and Frail Older Women

A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort

A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine

Effect of Melatonin on Cardiometabolic Risk- FULL

Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa

Statins to Prevent Cancer Associated Blood Clots

Dopamine and Sensorimotor Function in Stuttering

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity

Ketone Esters for Optimization of Operator Performance in Hypoxia

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

Randomized Trial of the Effectiveness of Topical "ABH Gel" vs. Placebo in Cancer Patients With Nausea

BCAAs in Concussion 2.0

Effect of Lithium Therapy on Long COVID Symptoms

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.

Wound Edge Changes Following Treatment With Santyl

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis